Milatuzumab demonstrated potent antitumor activity in preclinical models and showed early signs of clinical efficacy in hematologic malignancies, particularly in B cell lymphomas and multiple myeloma, where CD74 is highly expressed [91,92,93,94]. Here, CD74 is linked to hematologic disorder.